We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$338M
AUM Growth
-$66.5M
Cap. Flow
-$119M
Cap. Flow %
-35.14%
Top 10 Hldgs %
98.37%
Holding
23
New
–
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
TOST icon
Toast
TOST
+$35.8K
2
SNOW icon
Snowflake
SNOW
+$28.1K
3
CPNG icon
Coupang
CPNG
+$23.9K

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$78.8M
2
IOT icon
Samsara
IOT
+$16.7M
3
PATH icon
UiPath
PATH
+$12M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$10.7M
5
MASS icon
908 Devices
MASS
+$717K

Sector Composition

Rank Sector Weight
1 Technology 39.05%
2 Healthcare 25.91%
3 Financials 21.36%
4 Consumer Discretionary 13.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NU icon
1
Nu Holdings
NU
$73.6B
$72.2M 21.36%
9,152,548
-3,799
-0% -$23.3K
PATH icon
2
UiPath
PATH
$8.3B
$50.8M 15.03%
3,066,569
-750,000
-20% -$12M
DASH icon
3
DoorDash
DASH
$94B
$46.1M 13.64%
603,512
– –
IOT icon
4
Samsara
IOT
$23.2B
$42.8M 12.65%
1,543,447
-751,329
-33% -$16.7M
SNOW icon
5
Snowflake
SNOW
$114B
$38M 11.23%
215,708
+173
+0.1% +$28.1K
TXG icon
6
10x Genomics
TXG
$7.31B
$26.9M 7.96%
481,770
– –
ACRV icon
7
Acrivon Therapeutics
ACRV
$83.6M
$21.4M 6.34%
1,652,605
– –
ABOS icon
8
Acumen Pharmaceuticals
ABOS
$193M
$16.4M 4.86%
3,417,075
– –
OLK
9
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$13.2M 3.91%
705,514
– –
TARS icon
10
Tarsus Pharmaceuticals
TARS
$3.04B
$4.7M 1.39%
260,000
– –
SPRB
11
Spruce Biosciences
SPRB
$151M
$1.69M 0.5%
10,493
– –
MASS icon
12
908 Devices
MASS
$414M
$1.63M 0.48%
237,258
-89,169
-27% -$717K
CADL icon
13
Candel Therapeutics
CADL
$897M
$1.02M 0.3%
811,737
– –
TSHA icon
14
Taysha Gene Therapies
TSHA
$1.94B
$478K 0.14%
724,873
– –
CPNG icon
15
Coupang
CPNG
$29B
$147K 0.04%
8,438
+1,467
+21% +$23.9K
TOST icon
16
Toast
TOST
$20.1B
$142K 0.04%
6,287
+1,793
+40% +$35.8K
DDOG icon
17
Datadog
DDOG
$91.7B
$134K 0.04%
1,366
– –
CRWD icon
18
CrowdStrike
CRWD
$221B
$109K 0.03%
2,976
-480
-14% -$16.7K
ABSI icon
19
Absci
ABSI
$1.58B
$87.9K 0.03%
57,804
– –
CFLT
20
DELISTED
Confluent
CFLT
$47.8K 0.01%
1,354
– –
GTLB icon
21
GitLab
GTLB
$7.2B
$33.6K 0.01%
658
– –
KRTX
22
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-58,895
Closed -$10.7M
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-2,748,970
Closed -$78.8M

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q2 2023 Portfolio in Review

As of Q2 2023, Sands Capital Ventures held 23 positions worth $338M, down 16% from $405M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Sands Capital Ventures withdrew a net $119M in Q2 2023, closing 2 positions and reducing 5 holdings. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $78.8M position sold in full.

By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 36% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Sands Capital Ventures added an estimated $35.8K to Toast.

  • Sands Capital Ventures added most to Toast in Q2 2023, an estimated $35.8K increase.
  • Sands Capital Ventures's biggest Q2 2023 reduction was Samsara, cutting an estimated $16.7M.
  • Sands Capital Ventures fully exited DICE Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $78.8M.
  • Sands Capital Ventures's ten largest holdings make up 98% of its $338M portfolio in Q2 2023.
  • Sands Capital Ventures opened 0 new positions and closed 2 in Q2 2023.
  • Sands Capital Ventures's portfolio value fell 16% quarter-over-quarter to $338M.

Based on Sands Capital Ventures's 13F filing for Q2 2023, filed 15 Aug 2023.